Business Description
Dynavax Technologies Corp
NAICS : 325412
SIC : 2834
ISIN : US2681582019
Share Class Description:
DVAX: Ordinary SharesDescription
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.88 | |||||
| Equity-to-Asset | 0.63 | |||||
| Debt-to-Equity | 0.41 | |||||
| Debt-to-EBITDA | 11.34 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 2.33 | |||||
| Beneish M-Score | -3.58 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 57.8 | |||||
| 3-Year Book Growth Rate | 108.1 | |||||
| Future 3-5Y Total Revenue Growth Rate | 20.97 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 54.8 | |||||
| 9-Day RSI | 47.74 | |||||
| 14-Day RSI | 45.03 | |||||
| 6-1 Month Momentum % | -15.4 | |||||
| 12-1 Month Momentum % | 2.7 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 15.2 | |||||
| Quick Ratio | 14.1 | |||||
| Cash Ratio | 12.92 | |||||
| Days Inventory | 432.91 | |||||
| Days Sales Outstanding | 85.35 | |||||
| Days Payable | 33.56 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.5 | |||||
| Shareholder Yield % | 0.13 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 80.34 | |||||
| Operating Margin % | -10.82 | |||||
| Net Margin % | 3.91 | |||||
| FCF Margin % | 22.31 | |||||
| ROE % | 1.54 | |||||
| ROA % | 0.95 | |||||
| ROIC % | -14.21 | |||||
| ROC (Joel Greenblatt) % | 11.08 | |||||
| ROCE % | 1.6 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 185.17 | |||||
| Forward PE Ratio | 373.75 | |||||
| PE Ratio without NRI | 202 | |||||
| Price-to-Owner-Earnings | 108.93 | |||||
| PS Ratio | 6.64 | |||||
| PB Ratio | 2.35 | |||||
| Price-to-Tangible-Book | 2.36 | |||||
| Price-to-Free-Cash-Flow | 32.84 | |||||
| Price-to-Operating-Cash-Flow | 30.53 | |||||
| EV-to-EBIT | 68.76 | |||||
| EV-to-EBITDA | 45.29 | |||||
| EV-to-Revenue | 4.25 | |||||
| EV-to-Forward-Revenue | 3.6 | |||||
| EV-to-FCF | 19.06 | |||||
| Price-to-Projected-FCF | 2.27 | |||||
| Price-to-Median-PS-Value | 0.31 | |||||
| Price-to-Graham-Number | 4.61 | |||||
| Price-to-Net-Current-Asset-Value | 3.01 | |||||
| Price-to-Net-Cash | 4.08 | |||||
| Earnings Yield (Greenblatt) % | 1.45 | |||||
| FCF Yield % | 3.62 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:DVAX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Dynavax Technologies Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 236.149 | ||
| EPS (TTM) ($) | 0.06 | ||
| Beta | 1.17 | ||
| Volatility % | 23.5 | ||
| 14-Day RSI | 45.03 | ||
| 14-Day ATR ($) | 0.382967 | ||
| 20-Day SMA ($) | 11.4095 | ||
| 12-1 Month Momentum % | 2.7 | ||
| 52-Week Range ($) | 10.48 - 15.15 | ||
| Shares Outstanding (Mil) | 130.89 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Dynavax Technologies Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Dynavax Technologies Corp Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Dynavax Technologies Corp Frequently Asked Questions
What is Dynavax Technologies Corp(DVAX)'s stock price today?
The current price of DVAX is $11.11. The 52 week high of DVAX is $15.15 and 52 week low is $10.48.
When is next earnings date of Dynavax Technologies Corp(DVAX)?
The next earnings date of Dynavax Technologies Corp(DVAX) is 2024-08-02 Est..
Does Dynavax Technologies Corp(DVAX) pay dividends? If so, how much?
Dynavax Technologies Corp(DVAX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers